Go to article: Home | Access denied: the Impact trial Go to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: NewsGo to article: FargoGo to article: The pharma industry briefingGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Breast cancer timeline: charting three decades of successGo to article: PrEP drugs: is the NHS letting down patients at risk of HIV?Go to article: Swiss WorldCargoGo to article: Debate: can US pharma be taxed into behaving?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Can new therapies tackle the burden of endometriosis?Go to article: The rise of fake medicines in AfricaGo to article: Zenatek Go to article: Off-the-shelf CAR-T therapy: broadening the reach of precision medicineGo to article: Nobel Prize 2019: how a breathtaking discovery unlocked new drugsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: China in 2019: a prime destination for R&D deals Go to article: The global-local continuum: tips for a joined-up approach to Regulatory & PV outGo to article: Pharmacovigilance 2.0: reskilling for the digital & data science ageGo to article: Air France KLM Cargo Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue